Blueprint Medicines(BPMC) - 2023 Q1 - Earnings Call Transcript

Becker Hewes Operator Becker Hewes Following ASCO, we will continue enrollment in monotherapy cohorts and in parallel continued dose escalation of the combination of ribociclib in breast cancer patients. Second, we have our initial clinical data disclosure for BLU-451 in EGFR exon 20 mutant non-small cell lung cancer. These data will show safety and early clinical activity including evidence of CNS activity, that reinforced best-in-class potential for BLU-451. Thanks Becker. Earlier this morning, we've repo ...